Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2008
Date:11/7/2008


- Quarter Highlighted by Submission of NDA for Novel Antidepressant and

Steady Global Growth for Once-Daily Tramadol -

LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the third quarter ended September 30, 2008. All figures are in Canadian dollars unless otherwise stated.

"We are very pleased with the progress of our business," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Concomitant with the steady sales growth for our once-daily tramadol product globally, we have made strong progress in advancing the programs for our follow on products, highlighted by the submission, in the third quarter, of the NDA for DDS-04A, our novel SARI(1) antidepressant. Our significant efforts to date this year have positioned us to realize a number of value-driving milestones in 2009, including the potential approval of our once-daily tramadol formulation in the U.S., the potential approval and launch of DDS-04A in the U.S., the outcome of the pivotal Phase III study for our twice-daily tramadol-acetaminophen formulation, and the initiation of clinical studies for our first misuse and abuse deterrent combination product."

Financial Summary

Revenue from product sales of Labopharm's once-daily tramadol for the third quarter of fiscal 2008 increased to $3.9 million from $2.8 million for the third quarter of fiscal 2007. In-market sales (i.e. sales by the Company's marketing partners to end users) for once-daily tramadol for Europe(2) experienced strong growth with standard unit sales for the first eight months of 2008 growing by 97% compared to the same period of the previous year. Adjusted gross margin for the third quarter of fiscal 2008 increased to 60% from 56% for the third quarter of fiscal 2007. Research and development and selling, general and administrative expenses for the third quarter of fiscal 2008 were $11.2 million
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
2. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
3. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
4. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
5. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
6. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
7. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
8. Labopharm Reports Results for First Quarter Fiscal 2008
9. Labopharm announces details for first quarter results conference call and annual meeting
10. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
11. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DURHAM, NC -- Researchers have pinpointed the environmental source ... in Southern California for decades. It literally grows on ... project of a 13-year-old girl, who spent the summer ... Angeles hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... (HealthDay News) -- Not only is eating better and exercising ... of health-care dollars a year, a new study finds. ... health sciences at Wake Forest Baptist Medical Center in Winston-Salem, ... 2 diabetes patients. Participants ranged in age ... an intensive "lifestyle change program" focused on diet and exercise, ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2
... is associated with a statistically significant increase in cancer risk ... of the breast, liver, rectum, and upper aero-digestive tract combined, ... of the Journal of the National Cancer Institute. ... known about the impact of low to moderate alcohol consumption ...
... are sent to a cardiologist to go through a standard ... evidence of coronary artery disease which is the most common ... in men, and these women are sent home with little ... complaining of similar symptoms and are more likely to develop ...
... Postpartum depression is a seriousand often undiagnosedcondition affecting about ... the causes might include personal history of depression, stressful ... support. Left untreated, it can have lasting negative effects ... development. , In the first study of ...
... And that can pose a big public health threat, ... Following their release from Texas prisons, only 5 percent ... to treat their condition within the necessary 10 days, ... [antiretroviral therapy] at this time are at increased risk ...
... Experts agree that field needs more rigorous trials to aid ... of the guidelines for cardiac care issued by the American ... supported by the kind of gold-standard evidence that doctors respect ... come from heretics crying in the wilderness. One author of ...
... Telekenex, Inc ("Telekenex"), today announced it has ... MPLS network over the weekend from Straitshot Communications ... the challenge and worked straight through the weekend ... its network. One of these companies, Evergreen ...
Cached Medicine News:Health News:Million women study shows even moderate alcohol consumption associated with increased cancer risk 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Diabetes a risk factor for postpartum depression 2Health News:Most HIV-Infected Prisoners Go Untreated After Release 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 3Health News:Evergreen Healthcare and Others Successfully Migrate to the Telekenex Network From Straitshot 2
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Indiana blocked the sale of more ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Calif., Oct. 28 Watson Pharmaceuticals, Inc. (NYSE: ... announced today that its subsidiary Watson Laboratories, Inc. ... on outstanding patent litigation related to Watson,s Oxytrol® ... August 19, 2008, Barr submitted an Abbreviated New ...
... 27 Cambrex Corporation (NYSE: CBM ) announced that third quarter 2009 financial results will be ... conference call to discuss the third quarter 2009 financial results. , , ... 2009 Earnings Conference Call, When: ... 1-888-634-4003 for U.S., ...
Cached Medicine Technology:Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
Single-Piece PMMA Intraocular Lenses....
Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
STABIBAG Hydrophilic Acrylic Lens....
Medicine Products: